Sign in
Taking people in NorwayPhase 2

Tests anti-blood-vessel drugs in children with returning brain tumors

Tests low-dose drugs that block blood vessel growth in children with recurrent brain tumors.

Key facts

Who runs it
Medical University of Vienna
Where
Bergen, Oslo, and Trondheim, NorwaySee the 3 sitesAlso in 8 other countries, 31 sites
Registry title
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Status
Recruiting
Phase
Phase 2
People taking part
232 people, planned
Started
Apr 2014
Expected to end
Apr 2030
Type of study
Interventional, 2 groups
Treatments tested
  • Bevacizumab
  • Thalidomide
  • Celecoxib
  • Fenofibric acid
  • Etoposide
  • Cyclophosphamide
  • Cytarabine
  • Temozolomide (TMZ)
  • Irinotecan
Record updated
13 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people whose brain or spinal cord tumour (ependymoma, ATRT, medulloblastoma or another CNS tumour) has come back or is growing.

Age
Aged 0 to under 20 years at the time of the original diagnosis.
Sex
Female and male participants can join.
Disease stage
Relapsed or progressive medulloblastoma, ependymoma, ATRT or another CNS tumour. For three of the groups, at least one site of recurrent disease must be untreated. The tumour must be confirmed by tissue examination at diagnosis or relapse.
Earlier treatment
Treatment for the current relapse must not have been given; surgery before treatment is allowed. Earlier temozolomide/irinotecan treatment rules a person out of the main groups.
Biomarker or test result
For one medulloblastoma group, the tumour group must be confirmed by methylation testing.

Main reasons for not taking part

  • Active infection, pregnancy or breast feeding
  • Shunt dependency or earlier temozolomide/irinotecan (can join the exploratory group instead)
  • Known allergy to any drug in the protocol
  • Active stomach ulcer
  • Heart or blood vessel disease not controlled by standard treatment

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Stratum I: Relapsed or progressive medulloblastoma - completed
  • Stratum II: Relapsed or progressive ependymoma (at least one site of untreated recurrent disease)
  • Stratum III: Relapsed or progressive ATRT (at least one site of untreated recurrent disease)
  • Stratum IV: Relapsed or progressive medulloblastoma (at least one site of untreated recurrent disease)
  • Stratum V: Relapsed or progressive CNS tumor of various histologies or patients with exclusion criteria or adult patients (explorative)
  • Histological confirmation at diagnosis or relapse Stratum IV: Confirmation of the medulloblastoma group by methylation; IDAT (Intensity Data; raw data of methylation array)
  • Female or male, aged from 0 to <20 years (at time of original diagnosis)
  • Participants must have normal organ and bone marrow function (ALT <5x institutional upper limit of normal, creatinine <1.5x institutional upper limit of normal for age, WBC >1000/mm3, platelets > 20,000/mm3. Patients with values less than WBC 2000/mm3 or platelets 50,000/mm3 will require initiation of treatment with etoposide and cyclophosphamide at a lower starting dose as defined within the protocol
  • Karnofsky performance status ≥50. For infants and children less than 12 years of age, the Lansky play scale ≥50% will be used
  • Written informed consent of patients and / or legal guardian

Who cannot take part

  • Prior treatment with temozolomide/irinotecan (can be included in Stratum V)
  • Anticipation of the need for major elective surgery during the course of the study treatment
  • Non-healing surgical wound
  • Active infection, pregnancy or breast feeding
  • Treatment for current relapse (surgery may be performed before MEMMAT treatment; patients with sites of disease not irradiated are still eligible for the protocol)
  • Known hypersensitivity to any of the drugs in the protocol
  • Active peptic ulcer
  • Any significant cardiovascular disease not controlled by standard therapy e.g. systemic hypertension
  • Any disease or condition that contraindicates the use of the study medication/treatment or places the patient at an unacceptable risk of experiencing treatment-related complications
  • VP- or subdural peritoneal shunt dependency (can be included in Stratum V)
  • A bone fracture that has not satisfactorily healed

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

The criteria questions were written by an AI system from the criteria published for NCT01356290. Checked by software, not by a doctor.

  • What type of cancer has the patient been diagnosed with?
  • Is this cancer newly diagnosed, or has it come back or not responded to treatment?
  • Is the patient pregnant or breastfeeding?

This trial is currently available in Norway.

Also in 8 other countries, 31 sites

  • Helse Bergen HFBergen, NorwayTaking people
  • Oslo University Hospital HFOslo, NorwayTaking people
  • St. Olavs hospital HFTrondheim, NorwayTaking people

About the trial

What the trial wants to find out

Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities.

Read full original descriptionShow less

Antiangiogenesis therapy has emerged as a new treatment option in solid malignancies. The frequent delivery of low doses of chemotherapy, referred to as metronomic or antiangiogenic chemotherapy, targets endothelial cells while reducing the toxicity associated with standard dose chemotherapy.

The aim of the study is to extend therapy options for children with recurrent or progressive medulloblastoma, ependymoma, ATRT, and CNS tumors of various histologies, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life.

The study will be conducted in independent strata. Stratum I (recurrent medulloblastoma): recently completed (Peyrl, 2023). Stratum II (recurrent ependymoma), III (recurrent ATRT) and V (recurrent CNS tumors of various histologies, patients with exclusion criteria and adult patients): The primary objective is to determine the response rate defined as the percentage of patients with complete response (CR), partial response (PR), stable disease (SD) or lack of recurrence at 6 months after start of antiangiogenic treatment. Stratum IV (recurrent medulloblastoma): To determine whether temozolomide, irinotecan, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt can increase the response rate after 6 months of treatment, compared with etoposid, cyclophosphamide, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt. Additionally, PFS, OS, toxicity, QoL, performance status, predictive and prognostic markers will be examined.

In stratum II and III, the study will follow an open label, single arm phase 2 design, and an open label randomized two-arm phase 2 design in Stratum IV, and the exploratory Stratum V.

The 2 groups in the trial

  • Standard Arm (Stratum II, III, IV, V)Other group

    Etoposid, cyclophosphamide, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt

    Treatment: Bevacizumab, Thalidomide, Celecoxib, Fenofibric acid, Etoposide, Cyclophosphamide, and Cytarabine

  • Experimental arm (Stratum IV)Treatment being tested

    Temozolomide, irinotecan, bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide ivt, cytarabine ivt

    Treatment: Bevacizumab, Thalidomide, Celecoxib, Fenofibric acid, Etoposide, Cytarabine, Temozolomide (TMZ), and Irinotecan

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Plain-language title
Tests anti-blood-vessel drugs in children with returning brain tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT01356290, who can take part
Publications
Record updated
13 October 2026